TC-I 15 (Standard)
TC-I 15 (Standard) is the analytical standard of TC-I 15 (HY-107588). This product is intended for research and analytical applications. TC-I 15 (TC-I-15) is a type of allosteric collagen-binding integrin α2β1 inhibitor, and it also inhibits α1β1 and α11β1. TC-I 15 inhibits platelet adhesion to collagen and thrombus deposition. TC-I 15 prevents the formation of a pre-metastatic microenvironment by inhibiting the uptake of cancer-associated fibroblast (CAF) extracellular vesicles (EVs) by lung fibroblasts, which reduces the metastasis of salivary gland adenocystic carcinoma (SACC) to the lungs in mouse models, .
For research use only. We do not sell to patients.
- CAS No.: 916734-43-5
- Formula: C23H28N4O6S2
- Molecular Weight:520.62
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-12290
Arg-Gly-Asp-SerIntegrin Inhibitor -
HY-P0023
Cyclo(-RGDfK)αvβ3 Integrin Inhibitor -
HY-18644
CWHM-12αV Integrins Inhibitor -
HY-P0278
RGDTripeptide -
HY-14951
FirategrastIntegrin Antagonist -
HY-107588
TC-I 15α2β1 Inhibitor -
HY-100226
A-205804E-selectin/ICAM-1 Inhibitor -
HY-16141
CilengitideIntegrin Inhibitor -
HY-19307
SB-273005αvβ3/αvβ5 Receptor Antagonist -
HY-107589
BIO5192Integrin α4β1 Inhibitor -
HY-15770
TR-14035α4β7/α4β1 Antagonist -
HY-P1188
LDV-FITCα4β1 Binding Peptide
Biological Activity
Description
IC50 & Target
IC50: 0.4 μM (α2β1 to GLOGEN), 26.8 μM (α2β1 to GFOGER), 23.6 μM (α1β1 to GFOGER), 24.4 μM (α1β1 to GLOGEN), 177 μM (α11β1 to GLOGEN), 3177 μM (α11β1 to GFOGER)[1]
Chemical Information
-
CAS No. 916734-43-5
-
Molecular Weight 520.62
-
Formula C23H28N4O6S2
-
SMILES
O=[S](N(CSC(C)1C)[C@@H]1C(N[C@H](C(O)=O)CNC(NCC2=CC=CC=C2)=O)=O)(C3=CC=CC=C3)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
References
[1]. Emma J. Hunter, Selectivity of the collagen-binding integrin inhibitors, TC-I-15 and obtustatin. Toxicol Appl Pharmacol. 2021 Oct 1;428:115669. [Content Brief]
[2]. Jing Kong, et al. Extracellular vesicles of carcinoma-associated fibroblasts creates a pre-metastatic niche in the lung through activating fibroblasts. Mol Cancer. 2019 Dec 3;18(1):175. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
TC-I 15 (Standard) Related Classifications
HY-107588R Related Classifications
Powered by Bioz